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Summary The expression of allogenic lymphocyte-activating determinants (LAD) on 25 acute leukaemias
has been compared with the expression of cell-surface antigens identified by HLA-DR allo- and xeno-antisera.
The close correlation between LAD and DR known to occur on normal lymphocytes was not found in
leukaemias. Twenty-two LAD+ leukaemias included 2DR- cases, whilst 2LAD- leukaemias were DR'.
With the exception of 3 leukaemias all were strongly f2 microglobulin+. No correlation was found between
the % DR' cells and the level of lymphocyte stimulation. Separation of leukaemia cells on Ficoll gradients
into fractions containing different proportions of DR' cells did not correlate with LAD expression.
Furthermore, antisera to DR antigens only partially blocked leukaemic LAD. The results support the notion
that LAD on acute leukaemias are not necessarily associated with or identical to HLA-DR antigens, and that
the lymphocyte activating capacity of HLA-DR may be modulated.
Lymphocyte-activating determinants (LAD)
encoded by the HLA-D region of the human major
histocompatibility complex (MHC) are responsible
for stimulation of 3H-thymidine ([3H]-dT) uptake in
primary mixed lymphocyte culture (van Rood et al.,
1981). Acute leukaemias express lymphocyte-
activating determinants which stimulate autologous
and allogeneic lymphocytes (Taylor et al. 1976;
1977; Han et al., 1977). Family studies indicate that
LAD on leukaemic blasts may be encoded by the
MHC, though stimulation of autologous and HLA-
identical sib lymphocytes by these cells suggest the
expression of other, possibly leukaemia-specific,
LAD (Reinsmoen et al., 1978; Zier et al., 1980).
MHC-encoded LAD are closely associated, and
perhaps identical with serologically defined antigens
of the HLA-DR complex, expressed predominantly
by resting B lymphocytes (Bodmer, 1978). Most
acute myeloid leukaemias express cell-surface HLA-
DR (Schlossman et al., 1976; Janossy et al., 1977;
Newman & Greaves, 1982) which implies that such
cells should be LAD'. DR-associated LAD on
leukaemias may also stimulate autologous
lymphocytes, in the same way that the autologous
MLC induced by B lymphocytes (Opelz et al., 1975;
Kuntz et al., 1976) is under HLA-DR control
(Palacios et al., 1982). In this respect, leukaemic
LAD may correspond functionally to LAD
expressed by stem cells, in similar fashion to other
differentiation related antigens on leukaemias
(Greaves & Janossy, 1978) rather than to
neodeterminants induced by malignant
transformation.
Previous studies (Taylor et al., 1977) showed that
AML cells induce wide variations in lymphocyte
stimulation, which do not seem to be related to
the expression of DR-complex (Ta) antigens (Miale
et al., 1982). From similar observations in DR'
chronic lymphocytic leukaemia (Bom-van-Noorloos
et al., 1982) it has been suggested that
phenotypically expressed DR may be functionally
modulated as LAD.
In order to establish whether DR expression is
closely associated with LAD on acute leukaemias,
we have studied 25 cases containing high numbers
of blast cells, variable proportions of which are
DR . We found that DR expression was not
closely correlated with LAD, suggesting that DR
independent LAD are expressed by some
leukaemias, whilst on others, DR is functionally
inactive as an LAD.
Materials and methods
Cells
Heparinised peripheral blood from 25 acute
leukaemia patients, mostly with a high percentage
of blasts (.60%) was obtained before treatment.
Diagnoses were made on bone marrow and
peripheral blood smears, using standard cytological
methods (PAS, peroxidase, Sudan black, esterase).
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Leucocytes were separated on lymphocyte
separation medium (LSM, Flow Laboratories,
Scotland) as previously described (Taylor et al.,
1979). The leucocytes were washed in Hanks
Balanced Salt Solution containing 2% newborn calf
serum (HBS-NCS) then resuspended in RPM1-1640
containing 10% foetal calf serum (1640-FCS) and
10% dimethyl sulphoxide (DMSO). Differential
counts of leukaemias after LN2 storage showed
only minor changes in the proportion of cell types
(data not shown).
Normal lymphocytes were prepared from
peripheral blood by separation on LSM as above.
Responding and stimulating cells in MLC were
prepared in RPM1-1640 culture medium,
containing a 10% heat-inactivated human AB
serum (CM-AB).
Mixed leucocyte cultures (MLC)
Leukaemias and normal lymphocytes as stimulators
in MLC were inactivated in a 137Cs-irradiator (6K
rad). Responders and stimulators at 5 x 105ml- in
CM-AB were dispensed in quadruplicate into
microplates with round wells (M24 ART, Sterilin,
UK) as previously described (Taylor et al., 1979).
The microplates were incubated in humidified 95%
air/5% CO2 for 5 days, labelled overnight with
2 uCi per well methyl-(3H)-thymidine ([3H]-dT, sp.
act. 20Cimmol-1, Radiochemical Centre,
Amersham, UK) and harvested onto glass-fibre
filters using a Skatron/Titertek cell harvester (Flow
Laboratories, Scotland). The filters were dried and
counted in a toluene-based scintillant on a
Beckman LS3155T liquid scintillation counter.
Blocking of MLC was determined by adding
decomplemented antisera (see below - anti-DR,
p28,33 or f2m) directly to normal or leukaemic
MLCs on day 0, or by pretreating leukaemias with
antisera, washing then adding them to responding
lymphocytes.
Results of MLCs in countsmin-1 (cpm) [3H]-dT
uptake are expressed as:
1. cpm+s.d.
2. Stimulation indices (SI) =R x S/R+S, where
R x S is the cpm for the responder (R)
stimulated with the leukaemia(s) in MLC, and
R+S, the cpm for responders and stimulators
cultured alone. Leukaemias giving SI< 1.0 were
considered as LAD- and .2.0 as LAD+.
3. % Relative responses (RR) =
(R xS)-(R +S)
(R x pooled -(R x autologous x 100
allogeneic lymphocytes)
lymphocytes)
4. % MLC inhibition=
(R x S) Test antiserumx 100 (R x S) normal serum
Antisera
Rabbit antiserum to the p28,33 bimolecular
complex was a gift from Dr M.J. Crumpton (ICRF,
London, UK). In this paper it is referred to as
xeno-anti-DR serum, although such antisera
recognise a and ,B chains encoded by other class II
loci (Shackelford et al., 1982). Rabbit anti-fl2m was
obtained from Dakopatts (Copenhagen, Denmark).
Alloantisera were obtained from multiparous
females, kidney transplant recipients and leukaemic
patients immunized with allogeneic leukaemia cells,
and rendered B-cell specific by absorption with
packed, pooled blood platelets. These antisera were
selected on the basis of positive complement
dependent cytotoxic reactions on B-cells and
negative reactions on T cells (n=30). The B-cell
specificity was further tested on normal
lymphocytes by indirect membrane
immunofluorescence (IF, see below), combined with
sheep erythrocyte (E) rosetting. Briefly,
lymphocytes treated with alloantiserum and FITC-
conjugated anti-human Ig were rosetted with
neuraminidase-treated E overnight at 40 and
examined for evidence of IF staining of non-
rosetted (i.e. non-T) cells. Antisera giving such
reactions were selected, whilst antisera reacting with
rosetted (i.e. T) cells were rejected. Of the nine
alloantisera selected, 2 were operationally
monospecific for HLA-DR1 and DR5 in C-
dependent cytotoxicity assays. However, since the
objective was to identify most if not all DR
specificities, the sera were combined to give three
pools of three antisera. When further tested in
membrane IF, these antisera reacted with all
normal B cells, CLL cells, and B lymphoblastoid
cell lines, but not with the T cell lines Molt-4, or
CCRF-CEM. They are referred to as allo-anti-DR
sera throughout this paper though they almost
certainly contained antibodies to other HLA class
II allotypic determinants.
Immunofluorescence (IF) analysis
Viable leucocytes (106100 1 -1) were treated at 40
with 50-100,ul of xeno (p28,33) (1/10) or
polyspecific allo-anti DR (neat or 1/2) or anti-152m
(1/10-1/20) for 30min at 40, washed PBS and
stained with FITC-conjugated sheep anti-human Ig
(for DR antisera) or FITC sheep anti-rabbit Ig (for
p28,33 and fi2m) (Wellcome Laboratories,
Beckenham, UK). Control leucocytes were treated
with normal human or rabbit serum, and stained asLAD AND HLA-DR ON LEUKAEMIAS 487
above. Cells were finally washed three times,
resuspended in 50% glycerol in PBS and examined
under a Zeiss Universal epifluorescence microscope.
A minimum of 200 leucocytes in each
preparation were counted and the % positively
stained cells calculated. The % positive cells in the
control (normal sera treated) preparations were
subtracted in each instance, to give a corrected
percentage value. Cells were also scored for staining
intensity on a 0-3 scale (0=negative, 1+, 2+, and
3+ were respectively weak, intermediate and strong
positive). In a minority of cases where the number
of cells with Fc-bound human Ig was> 10%, the
difference in staining intensity between the allo-anti
DR-sera compared with the control was used to
assess whether DR was expressed. Since Fc
receptors and DR were co-expressed on these cells,
the % positively stained cells was computed on the
basis of staining intensity. Each cell was tested with
the three pooled antisera, and the pool giving the
highest percentage in each case taken as the % allo-
DR positive cells.
Double fluorochrome labelling of allo- and xeno-
DR antigens was performed by incubating
leucocytes sequentially with allo- and xeno- anti-
DR sera then staining with a mixture of equal parts
of 1/5 diluted FITC-F(Ab)2 goat anti-human Ig
and TRTC-F(Ab)2 goat anti-rabbit Ig (heavy and
light chain specific) antisera (Cappel Laboratories,
Cockranville, USA). The cells were examined under
a Leitz Dialux epifluorescence microscope using
TRITC and FITC filters and a 50 times water-
immersion objective. Only surface Ig negative
leukaemias were used in the analysis.
Results
HLA-DR expression by acute leukaemias
We studied 25 acute leukaemias, selected because
most contained_60% blasts. Diagnostically they
included 11 AML (cases 1-11), 2 undifferentiated
AML (cases 12 and 13), one atypical AML (case
14), 6 AML (cases 15-20), 2 AMOL (cases 21 and
22), 2 ALL (cases 23 and 24) and one CML in blast
crisis (case 25).
The percentage of cells expressing allo-DR was
compared with xeno-DR (p28,33) in membrane IF
analysis, and the results plotted in Figure 1. In
general the percentage of cells positive for both
antigens were similar, except cases 11, 16, 9, 10, 23
and 25. Nonetheless, there was a significant
correlation between the percentage of allo- and
xeno-DR+ cells (r=0.88, P<0.01).
However, to establish the steric relationship
between allo and xeno DR antigens cells from 6
cases were double fluorochrome labelled. Allo-DR
was detected by an FITC ainti-human Ig and xeno-
DR by a TRITC anti-rabbit Ig. Leukaemias were
treated either with allo-DR or xeno-DR antisera
alone or with both antisera sequentially, then with
a mixture of the FITC and TRITC conjugates.
Cells treated with one anti-DR serum only, reacted
specifically with the relevant conjugate (i.e. FITC
stained only allo-DR treated cells, TRITC stained
only xeno-DR treated cells). In sequentially
antiserum treated leukaemias, however, cells which
were allo-DR+ were also xeno-DR+. At the single
cell level, FITC and TRITC staining patterns
completely overlapped.
No correlation was found between the percentage
allo-DR+ cells and the percentage blasts (r=0.43,
P>0.05), as seen in Figure 2, indicating mixed
DR' and DR- populations of blasts in most
leukaemias. Only three leukaemias (cases 1, 2 and
5) contained <75% of f2m' cells; the remaining
cases contained strongly fl2m+ blasts.
Expression ofLAD on leukaemias
Figure 3 shows the leukaemias plotted according to
the expression of LAD in relation to the percentage
of DR' and f2m' cells. It is clear that cells
classified as LAD' (see Materials and methods)
contained quite different proportions of DR' cells;
in particular two LAD' leukaemias (Cases 4 and
18) were DR-. In addition, only one of the three
LAD- leukaemias was also DR-. A frequency plot
(not shown) indicates a bimodal distribution of
LAD+ leukaemias in groups with <20% and
>50% DR' blasts.
In Figure 4 the relationship between the level of
stimulation (% RR) by 8 cases tested on 14-16
responders, and DR expression is shown. The wide
distribution on RR values agrees with previous
results (Taylor et al., 1977) and bears little
relationship to the percentage DR' cells. Two cases
(4 and 12) containing 0 and 99% DR' cells were
respectively LAD' and LAD-. In addition three
leukaemias (5, 13 and 12) induced negative RR
values in a number of tests, perhaps indicating the
induction of suppression. No correlation was found
between mean RR and the % DR' cells or %
blasts (r=0.21 and r=0.05 respectively, P>0.1).
LAD onfractionated leukaemia cells
Freshly obtained AML cells (Case 9) were layered
over different densities of Ficoll/Hypaque (1.05-
1.10gml-1) in separate tubes, centrifuged for
30min at 300g, and the fractions analysed for LAD
and DR. Figure 5 shows the main cell types in each
fraction, with blasts predominating, particularly in
the 1.08gml-1 fraction. Lymphocytes were found
in the lighter density fractions, but myelocytes
formed an increasing proportion of cells collected0 16
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in the 1.08-1.10gml-l fractions. Cells from each
fraction stained for allo-DR showed a progressive
decrease in the proportion of DR' cells from
60% in the lowest to - 15% in the highest
density fraction. This contrasts with a marked
increase in lymphocyte stimulating (LAD')
capacity by cells in the high density fraction.
Effect ofantisera on leukaemic LAD
The role of DR as LAD on leukaemias was further
assessed by adding anti-DR sera directly to MLC
containing normal allogeneic lymphocytes of
leukaemias as stimulators. The specificity of
inhibition was compared with the effect of rabbit
anti-#2m. Figure 6 shows the result of two
experiments in which each leukaemia is identified
by its case number (4, 6, 11, 12, 18, 20, 22) together
with the intensity of staining for allo-DR. The
results show that both allo- and xeno-DR antisera
strongly block normal and leukaemic MLC, where
the leukaemias were strongly DR+ (Cases 6 and
12). However, blocking of leukaemic MLC by
xeno-anti-DR was weaker compared with anti-allo-
DR where the expression of DR was weaker (Cases
11, 20, 22). Furthermore, the two LAD' DR-
leukaemias were less markedly blocked by allo and
xeno anti-DR than the LAD on the DR'
leukaemias. Figure 6 shows that the anti-fl2m serum
blocked stimulation by normal and leukaemic
LAD.
To investigate the possibility that blocking might
be occurring at the level of the responders, four of
the leukaemias were pretreated with antisera, prior
to adding MLC. Free antibody was removed by
washing the stimulators to minimise the blocking
effect of excess antibody on the responding cells.
The results in Figure 7 clearly show that the anti-
DR and fl2m sera failed to block the stimulation of
allogeneic lymphocytes by these leukaemias, and in
cases 4 and 18 induced greater stimulation than in
the untreated controls.
Discugsion
This study is based on the notion that primary
LAD are closely associated, and possibly identical
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with serologically identified antigens of the HLA-
DR (class II) complex (Bodmer, 1978; van Rood et
al., 1981). The expression of DR antigens by B, but
not T lymphoid cell-lines, and their capacity to
induce lymphocyte stimulation (Romano & Mann,
1976) together with the inhibition of LAD by allo
and xeno antisera to DR (Albrechtsen et al., 1977;
Geier & Cresswell, 1977) is correborative evidence
of the close association between DR and LAD.
When we compared DR expression by acute
leukaemias with their capacity to stimulate primary
proliferative responses of normal lymphocytes, we
found however, that the DR phenotypic and LAD
functional moieties were poorly correlated. Our
results agree with Schlossman et al. (1976) and
Newman & Greaves (1982) that DR is expressed by
most myeloid leukaemias, but the % DR positive
cells was unrelated to the level of stimulation.
As previously reported by Janossy et al. (1977)
we found in IF analysis that DR (p28,33)
expression by myeloid leukaemias at the single cell
level was variable. We therefore determined both %
DR' cells, and an estimate of the intensity of DR
expression. Antigens of the DR complex were
identified by two types of reagent, of which the
rabbit anti-DR (p28,33 or Ta) antiserum is a well
characterised antibody reacting with the a (heavy)
and ,B (light) MW chains of the DR-complex (Snary
et al., 1977; Shackelford et al., 1982).
The human anti-DR alloantisera were selected to
cover as wide a spectrum as possible of all allotypes
encoded by HLA class II loci., so that a leukaemia
would not be regarded as HLA-DR-, simply
because the relevant antibody specificity was
absent. The alloantisera were elected from a panel
of mono- and poly-specific anti- B cell reagents,
depleted of antibody to class I antigens by platelet
absorption. Their selective reaction with B cells was
verified by complement-dependent cytotoxicity and
immunofluorescence. It can, however, be argued
that such alloantisera may contain other, non-DR
antibodies, identified in particular in IF analysis
which is recognised as more sensitive than
cytotoxicity. To verify that we were looking
predominantly, if not exclusively, at DR allotypic
reactions, we examined the distribution of labelling.
Not only did we find completely concordant
staining patterns for allo and xeno anti-DR on
individual cells, but we obtained no evidence that
different cells stained with each reagent, as would
probably have been the case if the alloantisera
contained non-HLA antibodies. Several authors
(reviewed by Shakelford et al., 1982) have
documented the biochemical and serological
relationship between the p28,33 biomolecular
complex, and DR allotypic determinants, indicating
that the latter are carried predominantly on the f
chains ofp28, 33.
In spite of reactions in IF by the anti-human-Ig-
FITC conjugate with Fc-bound cytophilic Ig on
certain AMLs, this was easily distinguished from
specific staining of DR allotypes both by intensity
and distribution. Allowance was thus made for the
background staining in calculating the percentage
DR' cells in a leukaemic population. The
percentage p28,33+ cells acted as a further means
ofverifying the estimate of DR' cells.
In this series we identified two cases (4 and 18),
containing no DR', cells which were particularly
potent stimulators and lymphocytes. The expression
of LAD by DR (Ta) negative acute leukaemia cells
has been reported by Han & Minowada (1978) who
described a "null-cell" ALL which produced the
MOLT 10 cell-line, both of which were
LAD+DR-. O'Keefe & Ashman (1982) showed
that LAD- leukaemia cell-lines became LAD'
following the addition of excess accessary cells to
MLC. The possibility that small numbers of DR'
cells, or that intracellular DR was the source of
stimulation cannot be excluded, but more studies
on these questions are required.
Although one DR- leukaemia was LAD-, as
expected, another containing 99% DR' cells failed
to stimulate. This effect is not likely to be due to
lack of viability of these cells in vitro, since previous
studies (Taylor et al., 1977) showed that irradiated
leukaemias remain viable for several days in vitro,
and also (unpublished observation) retain their
stimulating capacity. Lack of stimulation by DR'
leukaemic cells may be due to the modulation of
DR as a functional LAD, as suggested by Bom-
van-Noorloos et al. (1982) for the poor stimulating
capacity of CLL cells. An alternative explanation is
that DR may be suppressive when presented in
certain conformations, since we have shown that
autologous AML cells can inhibit MLC responses
(Taylor et al., 1979).
Previous studies showed that the level of
stimulation by acute leukaemia cells was both
responder and stimulator dependent, not related to
diagnosis, and in only a minority of cases,
correlated with shared HLA-A/B antigens on
responding and stimulating cells (Taylor et al.,
1977). A striking difference between leukaemic and
normal MLC is the spread of individual relative
response values in the former assays. This was
particularly evident for DR-LAD' leukaemias.
One reason for this may be that leukaemias express
a limited polymorphism of MHC - encoded LAD,
which might be disease related. A second
explanation may be that the LAD are encoded by
viral determinants and induce stimulation only of
immune allogeneic lymphocytes. Whatever the
explanation this point seems worthy of further
investigation, particularly in families.
The separation of fresh leukaemic cells intoLAD AND HLA-DR ON LEUKAEMIAS 493
fractions enriched for blasts or myelocytes
suggested that the latter were more stimulatory.
The absence of DR from myelocytes (Janossy et al.,
1977; Wernet et al., 1977; Ross et al., 1978) implies
that LAD may be expressed independently of DR.
It is also possible, however, that a minor DR+
population co-purifying with myelocytes is highly
stimulatory, as for instance are dendritic cells (van
Voorhis et al., 1982), or that blasts expressing DR
are intrinsically suppressive. Further clarification
requires functional analysis of pure populations of
leukaemia cells.
Anti-DR sera were only partially effective in
blocking leukaemic MLC, but much more effective
in blocking normal MLC. In addition, allo-DR
were more effective in blocking xeno-DR in 4/7
leukaemic MLC. This might indicate that xeno-DR
less effectively masks allotypic DR determinants, in
agreement with results reported by Miale et al.
(1982). It is also possible that blocking occurred at
the responder level in view of the expression of DR
by activated T cells (Indiveri et al., 1980). Such a
responder blocking effect has been observed in the
case of anti-fl2m by Ostberg et al. (1976) and may
be due to internalisation of antibody-antigen
complexes. In the case of fi2m antiserum, co-
capping of DR molecules, either on responder or
stimulator cells, could account for blocking. In view
of arguments that blocking of LAD by anti-DR
sera is direct evidence of identity (Shakelford et al.,
1982) the poor correlation between DR and LAD
on leukaemias must be viewed either as evidence of
separate identity, as functional modulation of DR,
or a combination of both.
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